← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #839 OF 1,000 MOST-CITED

Return to inventory--procedures

FDA cited this observation 22 times across 22 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation22
BY FISCAL YEAR
FY20251
FY20242
FY20231
FY20221
FY20194
FY20176
FY20167

How FDA worded it — real examples

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established, defined and documented.

Novutech LLC · Doral, Florida · Human Tissue for Transplantation · 2025-02-06

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not documented.

Eclipse Technology Solutions Inc · Chadds Ford, Pennsylvania · Human Tissue for Transplantation · 2024-05-01

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established.

Pure Life Orthopedic LLC · Camuy, Puerto Rico · Human Tissue for Transplantation · 2024-01-30

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established and implemented.

Mediwest Specialty Distribution LLC · Hormigueros, Puerto Rico · Human Tissue for Transplantation · 2022-12-20

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established.

Novus Surgical Solutions LLC · Allentown, Pennsylvania · Human Tissue for Transplantation · 2022-04-01

Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not defined, implemented and followed.

Evologics, LLC · San Antonio, Texas · Human Tissue for Transplantation · 2019-08-27

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →